Tags

Type your tag names separated by a space and hit enter

Bromperidol radioimmunoassay: human plasma levels.
J Pharm Sci. 1984 Apr; 73(4):546-8.JP

Abstract

A sensitive radioimmunoassay (RIA) procedure was developed to assay for bromperidol levels in human plasma after therapeutic drug administration. The antisera used in the RIA procedure was generated in rabbits against a haloperidol-bovine serum albumin conjugate. Tritiated haloperidol was used as the radioligand in the assay. A single ether extraction of alkalinized plasma was used to separate bromperidol from its more polar metabolites and to reduce assay variability encountered with a direct plasma assay. The lower limit of detection was approximately 0.5 ng/mL of parent drug in plasma. The assay exhibited within- and between-assay variabilities of approximately 9 and 14%, respectively. A 103-106% recovery of bromperidol from quality control plasma samples was observed over the concentration range of 1-150 ng/mL. A correlation coefficient of 0.9999 with respect to measured versus expected bromperidol content in the quality control plasma samples was exhibited. Cross-reactivity characteristics of the antisera indicated that dehydrobromperidol could significantly interfere (approximately 25% cross-reactivity) with the RIA procedure. However, biotransformation studies have not suggested this compound as a metabolite of bromperidol. Predose (Cmin) plasma levels of bromperidol in schizophrenic patients maintained on drug therapy are also reported.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

6726642

Citation

Tischio, J, et al. "Bromperidol Radioimmunoassay: Human Plasma Levels." Journal of Pharmaceutical Sciences, vol. 73, no. 4, 1984, pp. 546-8.
Tischio J, Hetyei N, Patrick J. Bromperidol radioimmunoassay: human plasma levels. J Pharm Sci. 1984;73(4):546-8.
Tischio, J., Hetyei, N., & Patrick, J. (1984). Bromperidol radioimmunoassay: human plasma levels. Journal of Pharmaceutical Sciences, 73(4), 546-8.
Tischio J, Hetyei N, Patrick J. Bromperidol Radioimmunoassay: Human Plasma Levels. J Pharm Sci. 1984;73(4):546-8. PubMed PMID: 6726642.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bromperidol radioimmunoassay: human plasma levels. AU - Tischio,J, AU - Hetyei,N, AU - Patrick,J, PY - 1984/4/1/pubmed PY - 1984/4/1/medline PY - 1984/4/1/entrez SP - 546 EP - 8 JF - Journal of pharmaceutical sciences JO - J Pharm Sci VL - 73 IS - 4 N2 - A sensitive radioimmunoassay (RIA) procedure was developed to assay for bromperidol levels in human plasma after therapeutic drug administration. The antisera used in the RIA procedure was generated in rabbits against a haloperidol-bovine serum albumin conjugate. Tritiated haloperidol was used as the radioligand in the assay. A single ether extraction of alkalinized plasma was used to separate bromperidol from its more polar metabolites and to reduce assay variability encountered with a direct plasma assay. The lower limit of detection was approximately 0.5 ng/mL of parent drug in plasma. The assay exhibited within- and between-assay variabilities of approximately 9 and 14%, respectively. A 103-106% recovery of bromperidol from quality control plasma samples was observed over the concentration range of 1-150 ng/mL. A correlation coefficient of 0.9999 with respect to measured versus expected bromperidol content in the quality control plasma samples was exhibited. Cross-reactivity characteristics of the antisera indicated that dehydrobromperidol could significantly interfere (approximately 25% cross-reactivity) with the RIA procedure. However, biotransformation studies have not suggested this compound as a metabolite of bromperidol. Predose (Cmin) plasma levels of bromperidol in schizophrenic patients maintained on drug therapy are also reported. SN - 0022-3549 UR - https://www.unboundmedicine.com/medline/citation/6726642/Bromperidol_radioimmunoassay:_human_plasma_levels_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-3549(15)46070-8 DB - PRIME DP - Unbound Medicine ER -